Angitia

Angitia Biopharmaceuticals

The company develops biologic therapies for patients with serious musculoskeletal diseases, including osteoporosis and osteogenesis imperfecta.

Skeletalis

This biotechnology company develops bone-targeted small-molecule therapies for patients with osteoporosis and other musculoskeletal diseases.

Novadip Biosciences

This company develops regenerative tissue products to treat patients with large bone defects, non-union fractures and spinal fusion requirements.

Ankyra Therapeutics

This biotechnology company develops anchored immunotherapy treatments for patients with cancer and other serious immune-mediated diseases.

Novadip

This company develops regenerative tissue products to treat large bone defects and spinal fusion for patients with limited treatment options.

Mereo BioPharma

The company develops clinical-stage therapies for patients with rare diseases, including osteogenesis imperfecta and alpha-1 antitrypsin deficiency-associated lung disease.

BOOST Pharma

This company develops an off-the-shelf therapy to treat children born with severe osteogenesis imperfecta, also known as brittle bone disease.

Engage Therapeutics

This biopharmaceutical company develops medicines for patients living with severe neurological and autoimmune conditions, including epilepsy, psoriasis and osteoporosis.